

DR. KEE THAI YEO (Orcid ID : 0000-0003-4357-3610)

DR. JU LEE OEI (Orcid ID : 0000-0003-0969-5884)

DR. DANIELE DE LUCA (Orcid ID : 0000-0002-3846-4834)

DR. GEORG SCHMOLZER (Orcid ID : 0000-0001-9798-2415)

Article type : Review Article

**Review of guidelines and recommendations from 17 countries highlights the challenges that clinicians face caring for neonates born to mothers with COVID-19**

**Authors**

1. Kee Thai Yeo MD MS, KK Women's & Children's Hospital, Singapore
2. Ju Lee Oei MBBS MD, Royal Hospital for Women, Randwick, NSW, Australia
3. Daniele De Luca MD MS, Division of Pediatrics and Neonatal Critical Care, "A. Bécclère" Medical Center, Paris Saclay University Hospitals, APHP, Paris, France; Physiopathology and Therapeutic Innovation Unit-INSERM U999, South Paris-Saclay University, Paris, France
4. Georg M. Schmölzer MD PhD, University of Alberta, Edmonton, Canada
5. Robert Guaran MBBS, NSW Perinatal Services Network, NSW Australia
6. Pamela Palasanthiran MBBS MD, Sydney Children's Hospital Network, Randwick, NSW, Australia
7. Kishore Kumar MBBS DCH MD, Cloud Nine Hospital Network, Bangalore, India
8. Giuseppe Buonocore MD, Azienda ospedaliera Universitaria Senese, Siena, Italy
9. Jeanie Cheong MBBS MD, Royal Women's Hospital, Parkville, Victoria, Australia; Clinical Sciences, Murdoch Children's Research Institute, Parkville, VIC; Dept of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC, Australia
10. Louise S Owen MBChB MD, Royal Women's Hospital, Melbourne, Victoria; ; Clinical Sciences, Murdoch Children's Research Institute, Parkville, VIC; Dept of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC, Australia.
11. Satoshi Kusuda MD PhD, Kyorin University, Tokyo, Japan.
12. Jennifer James MD, Children's Hospital of Philadelphia, PA, USA

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/apa.15495](#)

This article is protected by copyright. All rights reserved

13. Gina Lim MD, Ulsan University Hospital, South Korea
14. Ankur Sharma MBBS MD, Royal Hospital for Women, Randwick, NSW, Australia
15. Sabita Uthaya MBBS MD, Clinical Senior Lecturer and Consultant in Neonatal Medicine, Imperial College London and Chelsea and Westminster NHS Foundation Trust, UK
16. Christopher Gale MBBS PhD, Imperial College London and Chelsea and Westminster NHS Foundation Trust, London, UK
17. Elizabeth Whittaker MBCh BAO PhD, Imperial College London, UK
18. Cheryl Battersby MBBS PhD, Imperial College London and Chelsea and Westminster NHS Foundation Trust, London, UK
19. Neena Modi MBChB MD, Imperial College London, and Chelsea and Westminster NHS Foundation Trust Hospital, London, UK
20. Mikael Norman MD PhD, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
21. Lars Naver MD, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
22. Eric Giannoni MD, Department Mother-Woman-Child, Clinic of Neonatology, Lausanne University Hospital and University of Lausanne, Switzerland
23. Yenge Diambomba MD, Mount Sinai Hospital, Toronto, Ontario, Canada
24. Prakeshkumar S Shah MD MS, Mount Sinai Hospital, Toronto, Ontario, Canada
25. Luigi Gagliardi MD MS, Ospedale Versilia, Lido di Camaiore, AUSL Toscana Nord Ovest, Italy
26. Michael Harrison MBChB, University of Cape Town, Cape Town, South Africa
27. Shakti Pillay MBChB, Neonatologist, University of Cape Town, Cape Town, South Africa
28. Abdullah Alburaey MBBS, Iman Abdulrahman bin Faisal University, Dammam, Saudi Arabia
29. Yuan Yuan MD, Guangzhou Women and Children's Medical Center, People's Republic of China
30. Huayan Zhang MD, Guangzhou Women and Children's Medical Center, People's Republic of China; Children's Hospital of Philadelphia, USA; University of Pennsylvania Perelman School of Medicine, USA.

**Correspondence to:**

Kee Thai Yeo, MD MS FAAP

KK Women's & Children's Hospital,

100 Bukit Timah Road,

Singapore 229899

Email: yeo.kee.thai@singhealth.com.sg

Contact no: +65 63941244

**Short title:** Guiding neonatal care during the pandemic

**Abbreviations:** AGREE II, appraisal of guidelines for research and evaluation 2; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

## ABSTRACT

**Aim:** This review examined how applicable national and regional clinical practice guidelines and recommendations for managing neonates born to mothers with COVID-19 mothers were to the evolving pandemic.

**Methods:** A systematic search and review identified 20 guidelines and recommendations that had been published by 25 May 2020. We analysed documents from 17 countries: Australia, Brazil, Canada, China, France, India, Italy, Japan, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, the UK and the USA.

**Results:** The documents were based on expert consensus with limited evidence and were of variable, low methodological rigour. Most did not provide recommendations for delivery methods or managing symptomatic infants. None provided recommendations for post-discharge assimilation of potentially-infected infants into the community. The majority encouraged keeping mothers and infants together, subject to infection control measures, but one-third recommended separation. Although breastfeeding or using breastmilk were widely encouraged, two countries specifically prohibited this.

**Conclusion:** The guidelines and recommendations for managing infants affected by COVID-19 were of low, variable quality and may be unsustainable. It is important that transmission risks are not increased when new information is incorporated into clinical recommendations. Practice guidelines should emphasise the extent of uncertainty and clearly define gaps in the evidence.

**Keywords:** COVID-19, neonate, perinatal care, practice guidelines, transmission.

#### KEY NOTES

- A systematic search and review identified 20 guidelines and recommendations from 17 countries that had been published by 25 May 2020 on managing infants born mothers with COVID-19.
- All were based on expert consensus, with limited evidence, and were of variable, low methodological rigour.
- New information incorporated into clinical recommendations and guidelines should highlight any uncertainty, clearly define any gaps in the evidence and not increase transmission risks.



## INTRODUCTION

The World Health Organization (WHO) has now recorded more than half a million deaths worldwide due to the COVID-19 pandemic (1). It has been widely reported that COVID-19 disproportionately affects older people with underlying medical conditions (2). In the initial stages of the pandemic, the effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were thought to be relatively mild for pregnant women, newborn infants and children. However, there is now increasing evidence that this population can also be seriously affected, with some requiring high levels of medical care (3-6) and some dying (7).

Clinical practice guidelines and recommendations provide clinicians with management strategies for medical conditions that are based on the best available evidence (8). These guidelines and recommendations can decrease healthcare use and costs and improve consistency of practice, which can lead to better patient outcomes (9). Guidelines and recommendations should ideally be informed by the best available evidence, including well-designed randomised controlled trials. Acquiring robust and scientifically sound evidence takes time, often years, to generate (9), but this is not possible in a rapidly evolving situation like the COVID-19 pandemic.

Frontline action can have a significant impact on the outcome of infected patients in a pandemic. For example, several pressure points dictate the evolution of a successful pregnancy, including antenatal care, delivery management, postnatal care and discharge strategies. The initial recommendations during this pandemic were based on evidence gathered from areas with the highest infections levels, where social distancing and stringent lockdown procedures were paramount to containing the spread of the infection. However the impact of the pandemic has reduced in some countries and restrictions are being eased. This means that practices that were guided by the evidence on peak infections may not be applicable, or sustainable, in these populations.

The mother-infant dyad is a unique group, where infection has the potential to affect the mother and many others, including the newborn infant and other family members. The aim of this study was to critically evaluate the applicability of guidelines and recommendations from 17 countries that were developed during the initial stage of the COVID-19 pandemic. We wanted to see if

those recommendations, based on clinical evidence, would continue to be applicable and sustainable as the pandemic moves into different phases across the world.

## **METHODS**

### **Eligibility and search strategy**

We evaluated guidelines and recommendations for managing newborn infants born to mothers with suspected and confirmed COVID-19, which were published between 31 Dec 2019 to 25 May 2020. In view of the rapidly evolving situation, the search protocol was not pre-registered. Full text guidelines and recommendations that were available from neonatal and paediatric societies, public health organisations and governments, at state and national levels, in any language were included. Neonatal and paediatric organisations were also contacted directly. Institutional documents were obtained for countries without national or regional guidelines and recommendations. We prioritised guidelines from countries that were affected early in the course of the pandemic and the countries with the highest incidence of infection from every major WHO region by 1 May 2020. The guidelines and recommendations were independently assessed for eligibility by three review team members (KTY, JLO, AS). Disagreements were resolved through discussions with a fourth reviewer (HYZ).

### **Risk of bias quality assessment**

Two authors (KTY, AS) independently assessed the methodological quality of each of the guidelines and recommendations, excluding those from China, Singapore and South Africa, with the Appraisal of Guidelines for Research Evaluation II (AGREE II) instrument (10, 11). These three documents were not evaluated because two were institutional-based and the Chinese document was a summary of 10 different guidelines. The authors used a staged appraisal that initially evaluated Domain Three of the instrument, which covers the rigour of the development, for each of the guidelines and recommendations. Discrepancies of more than two points in the scores for the individual items were discussed and the scores adjusted, if necessary. Only guidelines and recommendations that had a quality score threshold of more than 70% for Domain Three were appraised for other domains. Scores for each domain were calculated by adding the scores from the individual reviewers and standardising them as a percentage of maximum possible scores, ranging from 0-100%.

### **Data extraction**

A standardised approach was used to extract data from each of the guidelines and recommendations and this was based on four themes. The first was antenatal care: identifying

and managing pregnant women. Second was delivery room management: where mothers and infant were placed, use of personal protective equipment and transporting neonates. Third was postnatal management: virus testing, isolation guidelines, breastfeeding and feeding using breastmilk, treatment of confirmed cases and visiting the neonate. Fourth was discharge and follow up. Guidelines and recommendations in any languages other than English were translated by native speaking authors.

### **Statistical analysis**

The AGREE II appraisal results were extracted and a descriptive statistical analysis of the means and standard deviations was undertaken using SPSS version 25.0 (IBM Corp, New York, USA).

### **Ethics review**

The authors did not request an ethics committee review, because this study focused on official documentation and no patients were involved.

## **RESULTS**

### **Characteristics of the guidelines and recommendations**

We identified 20 guidelines and recommendations from 17 countries that had been published by 25 May 2020. They included those that were affected early in the course of the pandemic: China (12-21), Japan (22), Singapore, South Korea (23) and Italy (24). The review also included those with a high incidence of infection from every major WHO region: Australia (25), Brazil (26), Canada (27-29), France (30), India (31), Saudi Arabia (32), South Africa, Spain (33), Sweden (34), Switzerland (35, 36), the UK (37) and the USA (38, 39). There were two guidelines and recommendations from the USA, the Centers for Disease Control and Prevention and the American Academy of Pediatrics, and three from Canada, from Toronto, Edmonton and the Canadian Pediatric Society. The 10 different guidelines and recommendations from China were collated and summarised by two authors (HZ, YY). At the time of the review, at least nine guidelines and recommendations had been revised at least twice.

### **Risk of bias and quality of guidelines**

The overall AGREE II Domain Three scores for rigour of development were low and highly variable, with a mean of  $8 \pm 7\%$  and a range of 2-33 (Table 1). India (33%), Italy (13%) and Spain (11%) had the highest scores in this category. The individual items that scored lowest focused on the lack of clear descriptions for: 'methods for formulating the recommendations are clearly

described', 'criteria for selecting the evidence are clearly described' and 'strengths and limitations of the body of evidence are clearly described' (11).

### **Specific areas covered by the documents**

#### **Antenatal care**

Seven guidelines provided specific recommendations for identifying and, or, managing pregnant women with suspected or confirmed COVID-19 during the antenatal period. These included recommendations for testing, according to established case definitions and risk profiles for COVID-19 (Table 2). China provided specific recommendations on using chest imaging and prescribing antenatal steroids.

#### **Delivery room management**

There were six guidelines and recommendations that recommended that delivery should be guided by the mother's obstetric needs: China, Toronto in Canada, India, Saudi Arabia, Sweden and Switzerland (Table 2). None of the documents provided specific recommendations for delivery methods, but China advocated a lower threshold for Caesarean deliveries if the women had severe COVID-19. Admission to a designated labour room or operating theatre was recommended by almost all of the guidelines and recommendations. Negative pressure rooms were recommended by five documents: Toronto in Canada, China, Singapore, South Korea and the American Academy of Pediatrics. N95 face masks, or equivalent, were recommended by 12 documents for aerosol generating procedures during newborn resuscitation, in addition to goggles, gowns and gloves. The postnatal recommendations varied considerably: 13 recommended rooming-in a healthy infant and infected mother, while six suggested separating the mother and infant until the mother tested negative.

#### **Postnatal infant management**

With regard to virologic testing, 14 documents recommended testing all infants born to COVID-19 mothers, regardless of maternal or infant symptoms. The testing methods for SARS-CoV-2 included nasopharyngeal, oropharyngeal and throat swabs and analysing them using reverse transcription polymerase chain reaction (RT-PCR) (Table 3). Four also recommended testing other specimens, such as placental swabs, cord blood, endotracheal aspirates, urine and stools. Recommendations for the timing of swabs were variable. Eight guidelines and recommendations suggested that swabs should be obtained between 0-72 hours and 10 suggested repeating swabs at 24-48 hours if the initial swabs were negative.

When it came to infection prevention and control practices, eight guidelines and recommendations suggested that infants should be cared for in negative pressure rooms, regardless of the symptoms and swab results (Table 3). Contact and droplet transmission-based precautions (40) were universally recommended, with the addition of N95 masks or equivalent (41) during aerosol generating procedures. Some suggested that a healthy infant and mother could be roomed-in together, but that the mother's bed and the infant's cradle or cot should remain two metres apart. The recommended duration of maternal-infant isolation was variable and ranged from the results of the infant virus tests to an empirical 14 days.

We found that 17 guidelines and recommendations supported using expressed breast milk to feed infants from asymptomatic, but infected, mothers (Table 3) and 15 of these also recommended breastfeeding. Singapore and South Korea did not recommend any breastfeeding by asymptomatic mothers or the use of breast milk. China recommended pasteurising expressed milk prior to feeding.

We also looked at aspects of newborn management, including visiting policies. This showed that 12 guidelines and recommendations allowed healthy caregivers and parents to visit newborn infants in the first days after delivery (Table 3). There were no specific recommendations for treating symptomatic newborn infants, but four - China, India, Spain and Sweden - specifically recommended against the use of antiviral therapy in infants.

### **Discharge and follow up**

The majority of the documents made provisions for follow up. Five suggested follow up via telehealth facilities using telephone and, or, video (Table 3). None provided suggestions about how potentially infected mother-infant dyads could be integrated into the community or with other infected member of the immediate family.

## **DISCUSSION**

At the beginning of the COVID-19 pandemic, there was little evidence that infants who were born to infected mothers were affected. However, by May 2020, several infants had positive RT-PCR virus results (42-47) and elevated SARS-CoV-2-specific immunoglobulin M (48, 49) within days of birth. This suggested *in utero* or intrapartum transmission. Indeed, the biological plausibility of perinatal infection has been underscored by the presence of the SARS-CoV-2 receptor, angiotensin-converting enzyme-2, in the placenta (50) and detection of the virus in amniotic fluid, placenta and breastmilk (4, 43, 47, 51-54). After the early postnatal period, late-onset infections

of SARS-CoV-2 have also been increasingly reported in infants, as a result of household and community transmission (53, 55, 56).

Therefore, management during delivery and the postnatal period have the potential to have a significant impact on the risk of infection for newborn infants born to mothers with COVID-19. Such strategies are strongly driven by clinical practice guidelines and recommendations, but the overall methodological quality of those we reviewed was low. They did not take into account whether the recommendations could be assimilated into the changing face of the pandemic, when social restrictions are lifted and the risk of a second wave emerges (57-59). The vagueness of the recommendations was probably inevitable, considering the speed and magnitude of the pandemic. However, at the time of this report, some countries were still experiencing huge numbers of infections that had not reached their peak. Synthesising recommendations from countries that were affected early in the course of the crisis, and comparing them with emerging evidence, will allow more newly affected countries to provide best management strategies and reduce the impact of the infection on mother-infant dyads. A summary of the recommendations is provided in Figure 1 and Table 4.

The most commonly used method to diagnose COVID-19 in infants is RT-PCR for SARS-CoV-2 in respiratory secretions from nasopharyngeal and oropharyngeal swabs. Most assays are based on detecting several SARS-CoV-2 gene targets (60). It should be noted that the performance of the different assays, which use different target genes, vary (61) and data on the performance of different assays in large populations of infants are lacking (62). Importantly, positive PCR results reflect the detection of viral ribonucleic acid and this does not indicate the viability of the virus (63). There are significant variations in the guidelines and recommendations with regards to the timing of initial infant testing. Recommendations to delay initial testing for the first 12-24 hours after birth are to account for potential contamination from maternal secretions. Earlier testing could be considered if there is an impact on where the newborn infant is placed and to establish whether the infection was *in utero*, intrapartum or postpartum (64). With increasing reports of late onset neonatal infections by the virus, any infant who presents with respiratory symptoms should trigger investigations for SARS-CoV-2 (53, 55, 56), especially in areas with ongoing community transmission. As the pandemic progresses, and antibody testing become more widely available, this may provide more evidence about the timing and routes of SARS-CoV-2 transmission and provide an alternative diagnostic method for neonatal COVID-19 (48, 49).

Delivery room practices are important during the pandemic. Emerging, but limited, reports of SARS-CoV-2 being detected in amniotic fluid, vaginal fluid and the placenta (43, 47) highlight the possibility of viral transmission and infection of the infant *in utero* and during delivery. Despite this, the vast majority of cases reported in the literature have indicated no substantial evidence for increased transmission risk during vaginal birth (65). Similarly, delayed cord clamping and provision of skin-to-skin contact with respiratory precautions have not been shown to increase the risk of viral transmission to the newborn infant. Having said that, there are significant variations in the guidelines and recommendations (52, 66). We can expect more evidence on the risks of viral transmission to emerge from systematic evaluations of specific COVID-19 clinical practices and infection control strategies in the delivery room. Any strategies in the guidelines and recommendations would need to evolve in parallel to provide safe and patient-centered care, especially in view of constrained resources and facilities, such as personal protective equipment and negative pressure rooms.

With regards to post-delivery management, there has been limited evidence on the risk of the virus being transmitted by infected mothers during skin-to-skin contact and by rooming-in of mothers and infants. Recommendations for separating mothers and their newborn infants should be made after consulting the parents. In the early stages of the crisis, countries such as China, Singapore and South Korea isolated infants from their infected mothers for up to 14 days to prevent the virus being transmitted to the infant. Guidelines developed at a later stage in other countries have not supported separation, but these recommendations will need to be constantly reviewed in light of an increasing number of reports that suggest that infants have been infected after birth (45, 67-72). The availability of local resources, and the local situation, may also heavily influence rooming options. These could include keeping the mother and infant together in a room, but for the infant's cradle or cot to be kept more than two metres from the mother's bed (73).

Even though a number of studies have reported that SARS-CoV-2 has been detected in breastmilk by RT-PCR (43, 51, 53, 54), the risk that newborn infants face from viral transmission and infection remains unclear. The detection of the immunoglobulin A immune response in breast milk after SARS-CoV-2 infection suggests that it is possible that breastmilk could provide infants with passive protection against SARS-CoV-2 (74). The act of breastfeeding, in addition to the breastmilk itself, provides the mother and baby with multiple short-term and long-term health and psychological benefits (75). In uninfected infants, a balance between preventing infection and the benefits of breastfeeding need to be considered. Nearly all of the guidelines and recommendations say that breast milk should be used, with most allowing breastfeeding if

suitable precautions are taken. The risks and benefits of this practice should be discussed with the parents, preferably before the infant is born.

The respiratory management and treatment of infants born to mothers with COVID-19 is another consideration. Antenatal steroids decrease the risk of adverse preterm infant outcomes (76-78), but may also pose a theoretical risk of worsening maternal viraemia (79, 80). Conversely, steroids reduce the cytokine storm, especially if maternal acute respiratory distress syndrome is evident (81). The use of antenatal steroids should be discussed in a multidisciplinary manner, on a case-by-case basis. Infants who need respiratory support should be managed according to local protocols (82), bearing in mind that using a high-flow nasal cannula, continuous positive airway pressure and other non-invasive ventilation methods may increase the risk of viral aerosolization (83). Ventilatory circuits equipped with high-efficiency particulate aerosol viral filters on their expiratory limb (84) should be considered, but the evidence for this in newborn care has been limited.

If we are to successfully adapt and cope with the changing phases of the pandemic, we need to exercise caution when interpreting and incorporating information into clinical recommendations. It is important that this process does not have a negative impact on infection prevention measures. The consensus and management strategies summarised in this review are drawn from the experiences of the countries that were affected early on in the current crisis and those with high burdens of disease. However, these will need to evolve with emerging evidence. To achieve this, we need to support international collaborations that acquire and collate data, to fill critical gaps and to support existing registries, databases and surveillance studies. Inadequately evidenced guidelines and recommendations may provide consistency, but they risk perpetuating practices that may be unhelpful or even harmful. If robust evidence is lacking, it would be beneficial for guidelines and recommendations to emphasise the extent of uncertainty and clearly define gaps in the evidence. They should also encourage healthcare practitioners and organisations to take part in national and international efforts to rapidly acquire and synthesise new information on the changing face of the COVID-19 pandemic.

## **CONCLUSION**

This review covered 20 guidelines and recommendations from 17 countries for caring for neonates born to mothers with COVID-19. All were based on expert consensus and limited evidence and were of variable, low methodological rigour. The COVID-19 pandemic poses a real challenge for clinicians caring for newborn infants, as new evidence is constantly emerging.



Accepted Article

Caution need to be exercised when interpreting and incorporating any new information into clinical recommendations, so that they do not have a negative impact on infection prevention measures. These documents should also emphasise the extent of any uncertainty in the information provided and clearly define any gaps in the evidence.

#### **CONFLICTS OF INTEREST**

The authors have no conflicts of interest to declare.

#### **FUNDING**

This research did not receive any external funding.

## REFERENCES

1. World Health Organization. Coronavirus disease (COVID-2019) situation reports. 2020
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.
3. Collin J, Bystrom E, Carnahan A, Ahrne M. Pregnant and postpartum women with SARS-CoV-2 infection in intensive care in Sweden. *Acta Obstet Gynecol Scand* 2020.
4. Vivanti A, Vauloup-Fellous C, Prevot S, Zupan V, Suffee C, Do Cao J, Benachi A, De Luca D. Transplacental transmission of SARS-CoV-2 infection. *Nat Commun* 2020; 11, 3572.
5. Savasi VM, Parisi F, Patane L, Ferrazzi E, Frigerio L, Pellegrino A, et al. Clinical Findings and Disease Severity in Hospitalized Pregnant Women With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol* 2020.
6. Sinelli M, Paterlini G, Citterio M, Di Marco A, Fedeli T, Ventura ML. Early Neonatal SARS-CoV-2 Infection Manifesting With Hypoxemia Requiring Respiratory Support. *Pediatrics* 2020; 146 1.
7. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE, et al. Maternal death due to COVID-19. *Am J Obstet Gynecol* 2020.
8. Institute of Medicine (U.S.). Committee on Standards for Developing Trustworthy Clinical Practice Guidelines., Graham R. Clinical practice guidelines we can trust. Washington, DC: National Academies Press, 2011.
9. Kredo T, Bernhardsson S, Machingaidze S, Young T, Louw Q, Ochodo E, et al. Guide to clinical practice guidelines: the current state of play. *Int J Qual Health Care* 2016; 28 1:122-8.
10. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ* 2010; 182 18:E839-42.
11. Agree Enterprise Consortium. The AGREE II Instrument [Electronic version]. [serial online] 2017 [cited]. Available from <http://www.agreetrust.org>.
12. Chinese Neonatal Association. Proposed prevention and control of 2019 novel coronavirus infection in neonates. *Clin J Perinat Med* 2020; 23 2:80-4.
13. Medical Association of the Chinese People's Liberation Army et al. Response plans in the neonatal intensive care unit during epidemic of SARS-CoV-2 infection *Chin J Contemp Pediatr* 2020; 22 3:205-10.

- Accepted Article
14. Working Group of the Prevention and Control of Neonatal 2019 nCoV Infection in the Perinatal Period of the Editorial Committee of Chinese Journal of Contemporary Pediatrics. Perinatal and neonatal management plan for prevention and control of 2019 novel coronavirus infection (1st Edition). Chin J Contemp Pediatr 2020; 22 2:87-90.
  15. Chen Z, Du LZ, Fu JF, Shu Q, Chen ZM, Shi LP, et al. [Emergency plan for inter-hospital transfer of newborns with SARS-CoV-2 infection]. Zhongguo Dang Dai Er Ke Za Zhi 2020; 22 3:226-30.
  16. Wang L, Shi Y, Xiao T, Fu J, Feng X, Mu D, et al. Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition). Ann Transl Med 2020; 8 3:47.
  17. Zhu H PS, Li H, Cheng Y, Wang H, Xia S. Common issues and solutions in the management of novel coronavirus infection in high-risk neonates. Zhonghua Er Ke Za Zhi 2020.
  18. Li X ZJ, Xu Y, Tao J, Zhang H, Sun X, Gong S. Guangdong expert consensus on the management of paediatric 2019-nCoV infection. Guangdong Medical Journal 2020.
  19. Qiao J et al. for Center for Obstetric Medical Quality Control. Management suggestion for pregnant women with novel corona virus pneumonia. Chinese Journal of Obstetrics and Gynecology 2020; 55 3:E007.
  20. Liu C et al for Liaoning Obstetric Quality Control Center. Suggestions for the management of pregnant women during 2019-novel coronavirus endemic in Liaoning province, China. Chinese Journal of Practical Gynecology and Obstetrics 2020; 2020 2:127-30.
  21. Maternal and Fetal Experts Committee, Chinese Physician Society of Obstetrics and Gynecology, Chinese Medical Doctor Association; Obstetric Subgroup, Society of Obstetrics and Gynecology, Chinese Medical Association, et al. Proposed management of 2019-novel coronavirus infection during pregnancy and puerperium. . Chin J Perinat Med 2020; 23 2.
  22. Japan Neonatal Society for Health and Development. Recommended measures to a new type of coronavirus infection in newborn infants. [Available from: <http://jsnhd.or.jp/pdf/202000326COVID-19.pdf>] accessed May 20 2020
  23. The Korean Neonatal Society 코로나바이러스감염증-19(COVID-19) 신생아 대응지침. [Available from: <http://www.neonatology.or.kr>] accessed 20 March 2020.

24. Società Italiana di Neonatologia. [Available from: <https://www.sin-neonatologia.it/indicazioni-sin/>] accessed 20 May 2020.
25. Department of Health and Human Services Victoria.. 2019 Novel Coronavirus (COVID-19) in Neonates. [Available from: <https://www.dhhs.vic.gov.au/>] accessed 23 March 2020.
26. Sociedade Brasileira de Pediatria. Prevenção e Abordagem da Infecção por COVID-19 em mães e Recém-Nascidos, em Hospitais-Maternidades. 2020
27. Alberta Health Services. Neonatal Management for 2019 Novel Coronavirus Infection (COVID-19). [Available from: <https://www.albertahealthservices.ca/topics/Page16947.aspx>] accessed 18 March 2020.
28. Shah PS DY, Whittle W, Barrett J, Science M, Hota S, Johnstone J and Toronto Region COVID-19 Hospital Operations Table. COVID-19 – Recommendations for Management of Pregnant Women and Neonates with Suspected or Confirmed COVID-19. Version March 26, 2020.: Maternal and Neonate Working Group TR-COVID-19-Hospital Operations Executive Table. Toronto, Ontario Canada.; March 31, 2020
29. Canadian Paediatric Society. NICU care for infants born to mothers with suspected or proven COVID-19. 2020
30. La Société Française de Néonatalogie. Concernant Les Nouveaux-Nés Dans Le Contexte D'épidémie à COVID-19 [Available from: <https://www.societe-francaise-neonatalogie.fr>] accessed 17 May 20.
31. National Neonatology Forum of India. Perinatal-Neonatal Management of COVID-19 infection. [Available from: [www.nnfi.org/cpg](http://www.nnfi.org/cpg)] accessed on 17 May 20
32. Saudi Arabia Ministry of Health . Saudi MOH Guideline for Neonate Born to Mothers with suspected or Confirmed COVID-19 infection [Available from <https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/Guideline-for-Neonate-born-to-COVID-19-Mother.pdf>] accessed 17 May 20
33. La Sociedad Española de Neonatología. Recommendations for management of newborns for SARS-CoV-2 infection. [Available from <https://www.seneo.es>] accessed 17 May 20
34. Svenska neonatalföreningen. Rekommendation om handläggning av barn till kvinnor med verifierad/sannolik Covid-19. Available from: [https://www.sfog.se/media/336903/rekommendation-om-handlaggning-av-barn-till-kvinnor-med-verifierad\\_sannolik-covid-19nationell.pdf](https://www.sfog.se/media/336903/rekommendation-om-handlaggning-av-barn-till-kvinnor-med-verifierad_sannolik-covid-19nationell.pdf)] Accessed 26 April 2020.

- Accepted Article
35. Swissnoso in collaboration with the Pediatric Infectious Disease Group of Switzerland (PIGS). Mesures dans les hôpitaux pour les enfants et les jeunes hospitalisés avec suspicion d'infection COVID-19 ou présentant une infection COVID-19 confirmée. [Available from: [https://www.swissnoso.ch/fileadmin/swissnoso/Dokumente/5\\_Forschung\\_und\\_Entwicklung/6\\_Aktuelle\\_Ereignisse/200320\\_Mesures\\_de\\_precautions\\_COVID-19\\_hopital\\_enfants\\_FR.pdf](https://www.swissnoso.ch/fileadmin/swissnoso/Dokumente/5_Forschung_und_Entwicklung/6_Aktuelle_Ereignisse/200320_Mesures_de_precautions_COVID-19_hopital_enfants_FR.pdf).] Accessed 28 April 2020.
  36. Gynécologie suisse SSGO. Recommandations SSGO Gynécologie Suisse: Infection à coronavirus COVID-19, Grossesse et accouchement. [ Available from: [https://www.sggg.ch/fileadmin/user\\_upload/Dokumente/1\\_Ueber\\_uns/Empfehlung\\_Coronavirusinfektion\\_COVID-19\\_24.03.2020\\_FR.pdf](https://www.sggg.ch/fileadmin/user_upload/Dokumente/1_Ueber_uns/Empfehlung_Coronavirusinfektion_COVID-19_24.03.2020_FR.pdf) ] accessed 31 Mar 2020.
  37. British Association of Perinatal Medicine. COVID-19 - guidance for paediatric services: Working in neonatal settings. [Available from: <https://www.rcpch.ac.uk>] accessed 20 May 20
  38. American Academy of Pediatrics. FAQs: Management of Infants Born to Mothers with Suspected or Confirmed COVID-19. [Available from: <https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/faqs-management-of-infants-born-to-covid-19-mothers/>] accessed 17 May 20
  39. Centers for Disease Control and Prevention, USA. Considerations for Inpatient Obstetric Healthcare Settings [Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html>] accessed 20 May 2020.
  40. Siegel JD RE, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee,. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. 2007
  41. Coia JE, Ritchie L, Adisesh A, Makison Booth C, Bradley C, Bunyan D, et al. Guidance on the use of respiratory and facial protection equipment. J Hosp Infect 2013; 85 3:170-82.
  42. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. The Lancet Infectious Diseases 2020.
  43. Kirtsman M, Diambomba Y, Poutanen SM, Malinowski AK, Vlachodimitropoulou E, Parks WT, et al. Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection. CMAJ 2020.

- Accepted Article
44. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during Pregnancy and Possible Vertical Transmission. *Am J Perinatol* 2020.
  45. Zeng L, Xia S, Yuan W, Yan K, Xiao F, Shao J, et al. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr* 2020.
  46. Wang S, Guo L, Chen L, Liu W, Cao Y, Zhang J, et al. A case report of neonatal COVID-19 infection in China. *Clin Infect Dis* 2020.
  47. Zamaniyan M, Ebadi A, Aghajanpoor Mir S, Rahmani Z, Haghshenas M, Azizi S. Preterm delivery in pregnant woman with critical COVID-19 pneumonia and vertical transmission. *Prenat Diagn* 2020.
  48. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. *JAMA* 2020.
  49. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. *JAMA* 2020.
  50. Li M, Chen L, Zhang J, Xiong C, Li X. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study. *PLoS One* 2020; 15 4:e0230295.
  51. Wu Y LC, Dong L, Zhang C, Chen Y, Liu J, Zhang C, Duan C, Zhang H, Mol BW, Dennis C, Yin T, Yang J, Huang H. Viral Shedding of COVID-19 in Pregnant Women SSRN 2020.
  52. Baud D, Greub G, Favre G, Gengler C, Jaton K, Dubruc E, et al. Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection. *JAMA* 2020.
  53. Buonsenso D, Costa S, Sanguinetti M, Cattani P, Posteraro B, Marchetti S, et al. Neonatal Late Onset Infection with Severe Acute Respiratory Syndrome Coronavirus 2. *Am J Perinatol* 2020.
  54. Gross R, Conzelmann C, Muller JA, Stenger S, Steinhart K, Kirchhoff F, et al. Detection of SARS-CoV-2 in human breastmilk. *Lancet* 2020.
  55. Frauenfelder C, Brierley J, Whittaker E, Perucca G, Bamford A. Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir. *Pediatrics* 2020.
  56. Coronado Munoz A, Nawaratne U, McMann D, Ellsworth M, Meliones J, Boukas K. Late-Onset Neonatal Sepsis in a Patient with Covid-19. *N Engl J Med* 2020; 382 19:e49.
  57. Xu S, Li Y. Beware of the second wave of COVID-19. *Lancet* 2020.

- Accepted Article
58. Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. *Lancet* 2020.
  59. New global cases spark fears of 2nd wave of Covid-19. *The Straits Times*
  60. World Health Organization. World Health Organization (2020) Novel Coronavirus (2019-nCoV) technical guidance: Laboratory testing for 2019-nCoV in humans.
  61. Nalla AK, Casto AM, Huang MW, Perchetti GA, Sampoleo R, Shrestha L, et al. Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. *J Clin Microbiol* 2020; 58 6.
  62. Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens. *J Clin Microbiol* 2020.
  63. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA* 2020.
  64. Shah PS, Diambomba Y, Acharya G, Morris SK, Bitnun A. Classification system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates. *Acta Obstet Gynecol Scand* 2020; 99 5:565-8.
  65. Luo Y, Yin K. Management of pregnant women infected with COVID-19. *The Lancet Infectious Diseases* 2020.
  66. Favre G, Pomar L, Qi X, Nielsen-Saines K, Musso D, Baud D. Guidelines for pregnant women with suspected SARS-CoV-2 infection. *The Lancet Infectious Diseases* 2020.
  67. Piersigilli F, Carkeek K, Hocq C, van Grambezen B, Hubinont C, Chatzis O, et al. COVID-19 in a 26-week preterm neonate. *Lancet Child Adolesc Health* 2020; 4 6:476-8.
  68. Ferrazzi E, Frigerio L, Savasi V, Vergani P, Prefumo F, Barresi S, et al. Vaginal delivery in SARS-CoV-2 infected pregnant women in Northern Italy: a retrospective analysis. *BJOG* 2020.
  69. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. *JAMA* 2020.
  70. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl Pediatr* 2020; 9 1:51-60.
  71. Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. *J Infect* 2020.



72. Zhang L, Jiang Y, Wei M, Cheng BH, Zhou XC, Li J, et al. [Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province]. *Zhonghua Fu Chan Ke Za Zhi* 2020; 55 0:E009.
73. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *JAMA* 2020.
74. Fox A MJ, Amanat F, Krammer F, Hahn-Holbrook J, Zolla-Pazner S, Powell RL. Evidence of a significant secretory-IgA-dominant SARS-CoV-2 immune response in human milk following recovery from COVID-19. *medRxiv* 2020050420089995.
75. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. 2020
76. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev* 2017; 3:CD004454.
77. Yeo KT, Thomas R, Chow SS, Bolisetty S, Haslam R, Tarnow-Mordi W, et al. Improving incidence trends of severe intraventricular haemorrhages in preterm infants <32 weeks gestation: a cohort study. *Arch Dis Child Fetal Neonatal Ed* 2019.
78. Crowley P, Chalmers I, Keirse MJ. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. *Br J Obstet Gynaecol* 1990; 97 1:11-25.
79. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. *The Lancet* 2020; 395 10225:683-4.
80. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *The Lancet* 2020; 395 10223:473-5.
81. Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med* 2020; 8 3:267-76.
82. De Luca D. Managing neonates with respiratory failure due to SARS-CoV-2. *The Lancet Child & Adolescent Health* 2020; 4 4.
83. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. *PLoS One* 2012; 7 4:e35797.
84. Demers RR. Bacterial/viral filtration: let the breather beware! *Chest* 2001; 120 4:1377-89.

## List of Tables/Figures

1. Table 1. Individual and overall standardised scores for rigour of development for 17 of the clinical practice guidelines and recommendations, using the AGREE II instrument
2. Table 2. Summary of reviewed guidelines for the antenatal and delivery room management of pregnant mothers with suspected or confirmed COVID-19
3. Summary of reviewed guidelines for the postnatal care of infants born to mothers with confirmed COVID-19
4. Table 4. Summary of recommendations for the postnatal care of infants born to women with COVID-19
5. Figure 1. Delivery room and operating theatre management of infants born of mother with suspected or confirmed COVID-19

**Table 1. Individual and overall standardised scores for rigour of development for 17 of the clinical practice guidelines and recommendations, using the AGREE II instrument**

| Rigour of development                                                                                | Australia    | Brazil       | Canada                |                      |              | France       | India        | Italy        | Japan        |
|------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|----------------------|--------------|--------------|--------------|--------------|--------------|
|                                                                                                      | Regional (%) | National (%) | Regional Edmonton (%) | Regional Toronto (%) | National (%) | National (%) | National (%) | National (%) | National (%) |
| Systematic methods were used to search for evidence                                                  | 0            | 0            | 0                     | 25                   | 0            | 8            | 67           | 17           | 8            |
| The criteria for selecting the evidence are clearly described                                        | 0            | 0            | 0                     | 8                    | 0            | 0            | 33           | 8            | 0            |
| The strengths and limitations of the body of evidence are clearly described                          | 0            | 0            | 0                     | 0                    | 0            | 0            | 17           | 17           | 8            |
| The methods for formulating the recommendations are clearly described                                | 0            | 0            | 0                     | 8                    | 0            | 0            | 17           | 0            | 0            |
| The health benefits, side effects, and risks have been considered in formulating the recommendations | 17           | 0            | 17                    | 0                    | 8            | 8            | 50           | 17           | 0            |
| There is an explicit link between the recommendations and the                                        | 17           | 8            | 17                    | 17                   | 8            | 8            | 50           | 25           | 8            |

|                                                                                 |   |    |   |    |   |   |    |    |    |
|---------------------------------------------------------------------------------|---|----|---|----|---|---|----|----|----|
| supporting evidence                                                             |   |    |   |    |   |   |    |    |    |
| The guidelines has been externally reviewed by experts prior to its publication | 8 | 17 | 0 | 17 | 0 | 0 | 17 | 17 | 17 |
| A procedure for updating the guidelines is provided                             | 8 | 0  | 8 | 0  | 0 | 0 | 17 | 0  | 8  |
| Overall Domain Score                                                            | 6 | 3  | 5 | 9  | 2 | 3 | 33 | 13 | 6  |

Organisations and institutions included – Australia: Victoria Neonatal Advisory Group; Brazil: Sociedade Brasileira de Pediatria; Canada: Edmonton Zone Section of Newborn Health, Toronto Region COVID-19 Hospital Operations Table, Canadian Paediatric Society; France: The French Society of Neonatology & French Pediatric Society; India: National Neonatology Forum; Italy: Italian Society of Neonatology; Japan: Japanese Society for Neonatal Health and Development; Saudi Arabia: Ministry of Health; South Korea: Korean Society of Neonatology; Spain: Spanish Society of Neonatology; Sweden: Swedish Perinatal Society; Switzerland: Swissnoso (Swiss National Center for Infection Prevention) and the Swiss Society of Obstetrics and Gynecology; UK: British Association of Perinatal Medicine; USA: Centers for Disease Control and Prevention, American Academy of Pediatrics.

Abbreviations: AAP-American Academy of Pediatrics; CDC-Centers for Disease Control and Prevention

| Rigour of development                                                                                | Saudi Arabia | South Korea  | Spain        | Sweden       | Switzerland  | UK           | USA              |                  |
|------------------------------------------------------------------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|------------------|------------------|
|                                                                                                      | National (%) | National (%) | National (%) | National (%) | National (%) | National (%) | National CDC (%) | National AAP (%) |
| Systematic methods were used to search for evidence                                                  | 0            | 0            | 8            | 0            | 0            | 8            | 0                | 0                |
| The criteria for selecting the evidence are clearly described                                        | 8            | 0            | 8            | 0            | 0            | 0            | 8                | 0                |
| The strengths and limitations of the body of evidence are clearly described                          | 8            | 17           | 17           | 0            | 0            | 17           | 17               | 0                |
| The methods for formulating the recommendations are clearly described                                | 0            | 0            | 0            | 0            | 0            | 0            | 0                | 0                |
| The health benefits, side effects, and risks have been considered in formulating the recommendations | 0            | 17           | 8            | 0            | 0            | 17           | 8                | 0                |
| There is an explicit link between the recommendations and the supporting evidence                    | 17           | 17           | 17           | 17           | 8            | 0            | 8                | 0                |
| The guidelines has been externally reviewed by experts prior to its publication                      | 0            | 17           | 17           | 8            | 8            | 8            | 17               | 8                |

|                                                     |    |    |    |   |   |    |    |   |
|-----------------------------------------------------|----|----|----|---|---|----|----|---|
| A procedure for updating the guidelines is provided | 42 | 17 | 17 | 0 | 0 | 25 | 17 | 8 |
| Overall Domain Score                                | 9  | 10 | 11 | 3 | 2 | 9  | 9  | 2 |

Organisations and institutions included – Australia: Victoria Neonatal Advisory Group; Brazil: Sociedade Brasileira de Pediatria; Canada: Edmonton Zone Section of Newborn Health, Toronto Region COVID-19 Hospital Operations Table, Canadian Paediatric Society; France: The French Society of Neonatology & French Pediatric Society; India: National Neonatology Forum; Italy: Italian Society of Neonatology; Japan: Japanese Society for Neonatal Health and Development; Saudi Arabia: Ministry of Health; South Korea: Korean Society of Neonatology; Spain: Spanish Society of Neonatology; Sweden: Swedish Perinatal Society; Switzerland: Swissnoso (Swiss National Center for Infection Prevention) and the Swiss Society of Obstetrics and Gynecology; UK: British Association of Perinatal Medicine; USA: Centers for Disease Control and Prevention, American Academy of Pediatrics.

Abbreviations: AAP-American Academy of Pediatrics; CDC-Centers for Disease Control and Prevention

**Table 2. Summary of reviewed guidelines for the antenatal and delivery room management of pregnant mothers with suspected or confirmed COVID-19**

|                                                            | Australia      | Brazil                                    |                                           | Canada                                                              |                | China                                                       | France         | India                                     | Italy                | Japan          | Saudi Arabia                              |
|------------------------------------------------------------|----------------|-------------------------------------------|-------------------------------------------|---------------------------------------------------------------------|----------------|-------------------------------------------------------------|----------------|-------------------------------------------|----------------------|----------------|-------------------------------------------|
| Distribution                                               | Regional       | National                                  | Regional (Edmonton)                       | Regional (Toronto)                                                  | National       | Regional/national                                           | National       | National                                  | National             | National       | National                                  |
| Version number                                             | 5              | Not specified                             | 3                                         | 2                                                                   | Not specified  | Summary                                                     | 2              | 2                                         | 3                    | 3              | Not specified                             |
| Date published                                             | 22 March       | 31 March                                  | 13 March                                  | 26 March                                                            | 6 May          | Feb/Mar                                                     | 16 March       | 7 May                                     | 10 May               | 23 March       | 12 April                                  |
| <b>Antenatal Care</b>                                      |                |                                           |                                           |                                                                     |                |                                                             |                |                                           |                      |                |                                           |
| Guidance for Identification & Management of Pregnant Women | None specified | None specified                            | None specified                            | Yes                                                                 | None specific  | Yes                                                         | None specified | Yes                                       | None specified       | None specified | Available in separate guideline           |
| <b>Delivery Room Management</b>                            |                |                                           |                                           |                                                                     |                |                                                             |                |                                           |                      |                |                                           |
| Mode of delivery                                           | None specified | None specified                            | None specified                            | According to obstetric assessment                                   | None specified | According to obstetric assessment                           | None specified | According to obstetric assessment         | None specified       | None specified | According to obstetric assessment         |
| Site of delivery                                           | Specific room  | Specific labour room or operating theatre | Specific labour room or operating theatre | Specific labour room or operating theatre, prefer negative pressure | Specific room  | Specific negative pressure labour room or operating theatre | None specified | Specific labour room or operating theatre | Specific labour room | None specified | Specific labour room or operating theatre |

|                                             |                                                              |                                            |                                                              |                                                  |                                                                 |                                           |                                                   |                                                   |                                                                    |                                                  |                                  |
|---------------------------------------------|--------------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------|--------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------|----------------------------------|
| PPE Advice during delivery                  | Surgical face mask; for AGP-N95; mask, goggles, gown, gloves | N95 mask, goggles, gown, gloves            | Surgical face mask; for AGP-N95; mask, goggles, gown, gloves | Droplet and contact precautions airborne for AGP | Droplet and Contact precautions, airborne if mother symptomatic | N95 mask, goggles, isolation suit, gloves | Surgical face mask; goggles, gown, gloves         | N95 mask, goggles, gown, gloves                   | N95 mask, goggles, gown, gloves                                    | Surgical face mask                               | Droplet and contract precautions |
| Separation of mother-infant after delivery  | Room with mother unless infant unwell                        | Room with mother if mother and infant well | Room with mother, unless infant or mother unwell             | Room with mother, unless mother or infant unwell | Room with mother                                                | Separate from mother                      | Room with mother unless infant or mother unwell # | Room with mother unless infant or mother unwell * | Room with mother, unless infant or mother has symptoms of COVID-19 | Room with mother, unless infant or mother unwell | Separate from mother             |
| Provisions for internal transport of infant | Yes with incubator                                           | Yes, with transport incubator              | Yes, with incubator                                          | Yes, with incubator                              | Yes, according to institutional practice                        | Yes, with transport incubator             | None specified                                    | None specified                                    | None specified                                                     | None specified                                   | Yes, with transport incubator    |

Organizations and institutions included: Australia: Victoria Neonatal Advisory Group; Brazil: Sociedade Brasileira de Pediatria; Canada: Edmonton Zone Section of Newborn Health, Toronto Region COVID-19 Hospital Operations Table, Canadian Paediatric Society; France: The French Society of Neonatology & French Pediatric Society; India: National Neonatology Forum; Italy: Italian Society of Neonatology; Japan: Japanese Society for Neonatal Health and Development; Saudi Arabia: Ministry of Health; Singapore: KK Women's & Children's Hospital; South Korea: Korean Society of Neonatology; South Africa: Groote Schuur Hospital; Spain: Spanish Society of Neonatology; Sweden: Swedish Perinatal Society; Switzerland: Swissnoso (Swiss National Center for Infection Prevention) and the Swiss Society of Obstetrics and Gynecology; UK: British Association of Perinatal Medicine; USA: Centers for Disease Control and Prevention, American Academy of Pediatrics.

\* Provisions made according to resources: if resources available and no evidence of community spread, for separation of mother and her infant

\*\* Separate guidelines endorsed by the Swiss Society of Neonatology

# for infants with congenital anomalies that may be worsened by SARS-CoV-2 infection, the guideline suggests consideration for separation of mother-infant on a case-by-case basis.

Abbreviations: AAP-American Academy of Pediatrics; AGP- Aerosol generating procedures; CDC- Centers for Disease Control and Prevention; PAPR- personal powered air respirators; PPE-personal protective equipment



**Table 2. Summary of reviewed guidelines for the antenatal and delivery room management of pregnant mothers with suspected or confirmed COVID-19**

|                                                            | Singapore                                    | South Korea                                                 | South Africa                                           | Spain          | Sweden                                    | Switzerland                       | UK                                                 | USA            |                                                             |
|------------------------------------------------------------|----------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------|----------------|-------------------------------------------|-----------------------------------|----------------------------------------------------|----------------|-------------------------------------------------------------|
| Distribution                                               | Institutional                                | National                                                    | Institutional                                          | National       | National                                  | National                          | National                                           | National (CDC) | National (AAP)                                              |
| Version no.                                                | 3                                            | 1                                                           | 2                                                      | 6              | 1                                         | Not specified**                   | Not specified                                      | Not specified  | Not specified                                               |
| Date published                                             | 8 May                                        | 6 March                                                     | 1 April                                                | 13 April       | 17 March                                  | 20 March 24 March                 | 13 May                                             | 20 May         | 21 May                                                      |
| <b>Antenatal Care</b>                                      |                                              |                                                             |                                                        |                |                                           |                                   |                                                    |                |                                                             |
| Guidance for Identification & Management of Pregnant Women | Yes                                          | Yes                                                         | None specified                                         | None specified | None specified                            | Yes                               | Available in separate guideline                    | Yes            | None specified                                              |
| <b>Delivery Room Management</b>                            |                                              |                                                             |                                                        |                |                                           |                                   |                                                    |                |                                                             |
| Mode of delivery                                           | None specified                               | None specified                                              | None specified                                         | None specified | According to obstetric assessment         | According to obstetric assessment | None specified                                     | None specified | None specified                                              |
| Site of delivery                                           | Specific negative pressure labour room or OT | Specific negative pressure labour room or operating theatre | None specified                                         | Single room    | Specific labour room or operating theatre | None specified                    | Specific labour room or operating theatre          | None specified | Specific negative pressure labour room or operating theatre |
| PPE Advice during delivery                                 | N95 mask, goggles, gown, gloves              | N95 mask, goggles, gown, gloves                             | Surgical face mask; for AGP-N95; mask, eye protection, | None specified | Surgical face mask, goggles, gown, gloves | Surgical mask                     | Surgical face mask, goggles (if splash procedure), | None specified | N95 mask with eye protection or PAPR, gown,                 |

|                                            |                      |                               |                                        |                                            |                                                     |                    |                                           |                               |                               |
|--------------------------------------------|----------------------|-------------------------------|----------------------------------------|--------------------------------------------|-----------------------------------------------------|--------------------|-------------------------------------------|-------------------------------|-------------------------------|
|                                            |                      |                               | gown, gloves                           |                                            |                                                     |                    | gown, gloves                              |                               | gloves                        |
| Separation of mother-infant after delivery | Separate from mother | Separate from mother          | Room with mother, unless infant unwell | Room with mother if mother and infant well | Rooming with mother, unless infant or mother unwell | Case-by-case basis | Rooming with mother, unless infant unwell | Consider temporary separation | Consider temporary separation |
| Provisions for transport of infant         | Yes, with incubator  | Yes, with transport incubator | None specified                         | Yes, with transport incubator              | None specified                                      | None specified     | Yes, with incubator                       | None specified                | None specified                |

Organizations and institutions included: Australia: Victoria Neonatal Advisory Group; Brazil: Sociedade Brasileira de Pediatria; Canada: Edmonton Zone Section of Newborn Health, Toronto Region COVID-19 Hospital Operations Table, Canadian Paediatric Society; France: The French Society of Neonatology & French Pediatric Society; India: National Neonatology Forum; Italy: Italian Society of Neonatology; Japan: Japanese Society for Neonatal Health and Development; Saudi Arabia: Ministry of Health; Singapore: KK Women's & Children's Hospital; South Korea: Korean Society of Neonatology; South Africa: Groote Schuur Hospital; Spain: Spanish Society of Neonatology; Sweden: Swedish Perinatal Society; Switzerland: Swissnoso (Swiss National Center for Infection Prevention) and the Swiss Society of Obstetrics and Gynecology; UK: British Association of Perinatal Medicine; USA: Centers for Disease Control and Prevention, American Academy of Pediatrics.

\* Provisions made according to resources: if resources available and no evidence of community spread, for separation of mother-child

\*\* Separate guidelines endorsed by the Swiss Society of Neonatology

# for infants with congenital anomalies that may be worsened by SARS-CoV-2 infection, the guideline suggests consideration for separation of mother-infant on a case-by-case basis.

Abbreviations: AAP-American Academy of Pediatrics; AGP- Aerosol generating procedures; CDC-Centers for Diseases Control and Prevention; PAPR- personal powered air respirators; PPE-personal protective equipment

Table 3. Summary of reviewed guidelines for the postnatal care of infants born to mothers with confirmed COVID-19

|                                   | Australia                                                              | Brazil         |  | Canada                                            |  | China                                                                 | France   | India                                                           | Italy    | Japan                                                                                       | Saudi Arabia |
|-----------------------------------|------------------------------------------------------------------------|----------------|--|---------------------------------------------------|--|-----------------------------------------------------------------------|----------|-----------------------------------------------------------------|----------|---------------------------------------------------------------------------------------------|--------------|
|                                   | Regional                                                               | National       |  | Regional (Edmonton)                               |  | Regional/National                                                     | National | National                                                        | National | National                                                                                    | National     |
| Indications for testing of infant | If mother is positive and infant is symptomatic                        | None specified |  | If mother is positive or infant is symptomatic    |  | If mother is positive or infant is symptomatic                        |          | If mother is positive or with exposure to persons with COVID-19 |          | If mother is positive                                                                       |              |
| Method of testing                 | None specified*                                                        | None specified |  | NP/Throat swab PCR                                |  | NP swab                                                               |          | NP/OP swab; ET aspirate if mechanically ventilated              |          | Pharyngeal swab                                                                             |              |
| Timing of testing                 | None specified                                                         | None specified |  | When mother confirmed positive                    |  | If symptomatic or when mother confirmed positive                      |          | Second day of life, or at least >12h after delivery             |          | At birth or when mother confirmed positive, Repeat after 5-14 days if initial test negative |              |
| Isolation facility                | Single room preferred; Negative pressure if moderate/ severe symptoms; | Single room    |  | Single room; Negative pressure if severe symptoms |  | Single room; Negative pressure if require AGP                         |          | Single room                                                     |          | Single room                                                                                 |              |
| Length of infant isolation        | Depends on maternal and infant virologic testing, for 14 days          | None specified |  | Single room; Negative pressure if severe symptoms |  | Single room; negative pressure if infant requires respiratory support |          | Separate isolation unit, negative pressure preferred            |          | Single room                                                                                 |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |
|                                   |                                                                        |                |  |                                                   |  |                                                                       |          |                                                                 |          |                                                                                             |              |

|                                                  |                                                                                                     |                                                          |                                                                                                     |                                                            |                                                     |                                                        |                                                                    |                                                                  |                                                                     |                                |                                |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------|------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------|--------------------------------|
| Transmission based precautions for infant care # | Contact and Droplet precaution; N95 mask for AGP; Airborne, Contact and Droplet if severe infection | Contact and Droplet precautions; N95 mask for AGP        | Contact and Droplet precaution; N95 mask for AGP; Airborne, Contact and Droplet if severe infection | Contact and Droplet precaution; Airborne preferable if AGP | According to local infection prevention and control | Airborne, Contract and Droplet precaution,             | Contact and Droplet precaution                                     | Contact and Droplet precaution; N95 mask for AGP                 | Contact and Droplet precaution (only surgical mask for the mothers) | Contact and Droplet precaution | Contact and Droplet precaution |
| Breastfeeding / Expressed breastmilk             | Allow BF, EBM                                                                                       | Allow BF, EBM                                            | Allow BF, EBM                                                                                       | Allow BF, EBM                                              | Allow BF, EBM                                       | No BF, Allow pasteurised EBM                           | Allow BF, EBM                                                      | Allow BF, EBM (if mum symptomatic)                               | Allow BF, EBM (if mum symptomatic)                                  | Allow EBM                      | Allow EBM                      |
| Visitation policy                                | Allow well and non-suspect mother and partner                                                       | Asymptomatic parents according to institution guidelines | None specified                                                                                      | Negative tested parents allowed in NICU                    | Asymptomatic and negative mother                    | No visitors                                            | Father, mother/legal caregiver if asymptomatic, with surgical mask | Family member not in contact with mother or other suspect /cases | No visitation by relatives or friends                               | Mother                         | No visitors                    |
| Treatment recommendation for newborn             | None specified                                                                                      | None specified                                           | Yes                                                                                                 | None specified                                             | None specified                                      | Yes                                                    | None specified                                                     | Yes                                                              | None specified                                                      | None specified                 | None specified                 |
| Respiratory management recommendation            | None specified                                                                                      | None specified                                           | Yes                                                                                                 | Yes                                                        | None specified                                      | Yes                                                    | None specified                                                     | Yes                                                              | None specified                                                      | Monitoring of infant           | None specified                 |
| Provision of antivirals                          | None specified                                                                                      | None specified                                           | None specified                                                                                      | None specified                                             | None specified                                      | Not recommended                                        | None specified                                                     | Not recommended                                                  | None specified                                                      | None specified                 | None specified                 |
| Discharge indications                            | Depends on symptoms and maternal and infant virologic test                                          | None specified                                           | Depends on symptoms and maternal and infant virologic test                                          | If well                                                    | None specified                                      | Improved symptoms, PCR test negative x 2 (1 day apart) | None specified                                                     | Depending on symptoms up to 10 days                              | After 5-7 days if PCR test negative                                 | None specified                 | PCT test negative x 2          |

|                           |                                              |                |                               |                                      |                |                                                                           |                             |                                             |                                                             |                   |                                          |
|---------------------------|----------------------------------------------|----------------|-------------------------------|--------------------------------------|----------------|---------------------------------------------------------------------------|-----------------------------|---------------------------------------------|-------------------------------------------------------------|-------------------|------------------------------------------|
| Home isolation            | Discuss with<br>Infection Prevention<br>team | None specified | According to<br>public health | According to<br>public health        | None specified | 14 days                                                                   | 14 days                     | None specified                              | At least 14 days                                            | None<br>specified | None specified                           |
| Follow-up<br>appointments | Use telehealth<br>facilities                 | None specified | None specified                | 48h-72h visit<br>with<br>precautions | None specified | Follow up by<br>telephone 3,7,14<br>days or in person<br>at 2 and 4 weeks | Follow up within 1<br>month | Telephone follow<br>up or visiting<br>nurse | Follow-<br>up with PCR test<br>at 20 and 30 days<br>of life | None<br>specified | Frequent follow<br>up through 14<br>days |

Organizations and institutions included: Australia: Victoria Neonatal Advisory Group; Brazil: Sociedade Brasileira de Pediatria; Canada: Edmonton Zone Section of Newborn Health, Toronto Region COVID-19 Hospital Operations Table, Canadian Paediatric Society; France: The French Society of Neonatology & French Pediatric Society; India: National Neonatology Forum; Italy: Italian Society of Neonatology; Japan: Japanese Society for Neonatal Health and Development; Saudi Arabia: Ministry of Health; Singapore: KK Women’s & Children’s Hospital; South Korea: Korean Society of Neonatology; South Africa: Groote Schuur Hospital; Spain: Spanish Society of Neonatology; Sweden: Swedish Perinatal Society; Switzerland: Swissnoso (Swiss National Center for Infection Prevention) and the Swiss Society of Obstetrics and Gynecology; UK: British Association of Perinatal Medicine; USA: Centers for Disease Control and Prevention, American Academy of Pediatrics.

\* available in a separate associated guideline

\*\* provisions made according to resources: if resources available and no evidence of community spread, for separation of mother and her infant

\*\*\* Separate guidelines endorsed by the Swiss Society of Neonatology

# Appropriate PPE for following: contact precautions: use of gown, gloves, surgical mask; droplet precautions: addition of protective eyewear; airborne precautions: use of N95 mask or equivalent

Contact and droplet: use gown, gloves, surgical mask and eye protection. Contact and Droplet and Airborne: use gown, gloves, eye protection plus N95 mask or equivalent, and preferably in negative pressure room

Abbreviations: AAP-American Academy of Pediatrics; AGP-aerosol generating procedures; CDC- Centers for Disease Control and Prevention; BAL- bronchoalveolar lavage; BF-breastfeeding, EBM-expressed breastmilk; ET- endotracheal; LR- lower respiratory; NP-nasopharyngeal; OP-oropharyngeal; PCR-polymerase chain reaction

**Table 3. Summary of reviewed guidelines for the postnatal care of infants born to mothers with confirmed COVID-19**

|                                                  | Singapore                                | South Korea                                            | South Africa                                                            | Spain                                                        | Sweden                                             | Switzerland                                 | UK                                                           | USA                                                               |                                                                                                |
|--------------------------------------------------|------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------|----------------------------------------------------|---------------------------------------------|--------------------------------------------------------------|-------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
|                                                  | Institutional                            | National                                               | Institutional                                                           | National                                                     | National                                           | National ***                                | National                                                     | National (CDC)                                                    | National (AAP)                                                                                 |
| Indications for testing of infant                | If mother is positive                    | If mother is positive                                  | If mother is suspected or confirmed and infant symptomatic              | If mother is positive                                        | If mother is positive                              | None specified                              | If mother is confirmed and infant symptomatic                | If mother is positive                                             | If mother is positive                                                                          |
| Method of testing                                | NP swab PCR                              | NP/OP swab PCR                                         | NP/Throat swab PCR                                                      | NP/OP swab, BAL/ET aspirate, blood, stool, urine PCR         | NP swab PCR                                        | None specified                              | Nasal swab                                                   | NP/OP/Nasal swab PCR                                              | NP/Throat swab PCR                                                                             |
| Timing of testing                                | Two swabs on consecutive days            | Two swabs 48h apart                                    | When symptomatic or >72h and repeated on day 5                          | Two swabs, one at 24h and ≥48h                               | >4h after delivery                                 | None specified                              | 72 hours after birth and repeated on day 5                   | Two swabs, at 24h and 48h                                         | Two swabs, one at 24h and 48h                                                                  |
| Isolation facility                               | Single room, negative pressure           | Single room                                            | Single room                                                             | Single room, negative pressure if risk of aerosol generation | Single room; negative pressure for infected infant | Single room                                 | Single room preferred                                        | None specified                                                    | Single room; negative pressure preferred.                                                      |
| Length of infant isolation                       | Length to be determined                  | Depends on infant virologic testing                    | If positive, until resolution of symptoms and off respiratory support   | Depends on maternal and infant virologic testing             | None specified                                     | 10 days after symptoms and 48h asymptomatic | 14 days and infant tests negative                            | None specified                                                    | None specified                                                                                 |
| Transmission based precautions for infant care # | Airborne, Contact and Droplet precaution | Contact and Droplet precaution; N95/P2 masks preferred | Contact and Droplet precaution; Airborne precaution and N95 mask if AGP | Contact and Droplet precaution                               | Contact and Droplet precaution                     | Contact and Droplet precaution; N95 for AGP | Contact and Droplet precaution; N95 mask for AGP if positive | Referral to IPC Guidance document; Contact and Droplet precaution | Contact and Droplet precaution; Airborne precaution if requires CPAP or mechanical ventilation |

|                                             |                |                                        |                                     |                                                           |                               |                   |                                                       |                                   |                                                      |
|---------------------------------------------|----------------|----------------------------------------|-------------------------------------|-----------------------------------------------------------|-------------------------------|-------------------|-------------------------------------------------------|-----------------------------------|------------------------------------------------------|
| Breastfeeding /<br>Expressed<br>breastmilk  | No BF,EBM      | No BF,EBM                              | Allow BF, EBM                       | Allow BF, EBM                                             | Allow BF, EBM                 | Allow BF, EBM     | Allow BF, EBM                                         | Allow BF, EBM                     | Allow BF, EBM                                        |
| Visitation policy                           | No visitors    | None specified                         | No visitation by<br>positive mother | Allow parents or<br>caregiver (if<br>negative)            | Healthy<br>caregiver          | Allow caregiver   | Allow parents (if<br>asymptomatic<br>and/or negative) | Allow healthy<br>parent/caregiver | Allow parents if not<br>suspected with<br>COVID-19   |
| Treatment<br>recommendation<br>for newborn  | None specified | None specified                         | None specified                      | Yes                                                       | None specified                | None<br>specified | None specified                                        | None specified                    | None specified                                       |
| Respiratory<br>management<br>recommendation | None specified | None specified                         | Yes                                 | Yes                                                       | None specified                | None<br>specified | Yes                                                   | None specified                    | None specified                                       |
| Provision of<br>antivirals                  | None specified | None specified                         | None specified                      | Not<br>recommended                                        | Not<br>recommended            | None<br>specified | None specified                                        | None specified                    | None specified                                       |
| Discharge<br>indications                    | None specified | Asymptomatic, PCR<br>test negative x 2 | None specified                      | Improved<br>symptoms, PCR<br>test negative<br>over 3 days | Standard<br>criteria          | If well           | If well                                               | When well                         | According to unit<br>criteria                        |
| Home isolation                              | None specified | None specified                         | None<br>specified                   | None specified                                            | According to<br>public health | Not specified     | None specified                                        | Per local health<br>dept          | None specified                                       |
| Follow-up<br>appointments                   | None specified | None specified                         | Regular follow-up                   | In two weeks<br>(telephone)                               | None specified                | With midwife      | Telephone or video<br>follow-up                       | Close outpatient<br>follow-up     | Frequent follow up<br>thought 14 days<br>after birth |

Organizations and institutions included: Australia: Victoria Neonatal Advisory Group; Brazil: Sociedade Brasileira de Pediatria; Canada: Edmonton Zone Section of Newborn Health, Toronto Region COVID-19 Hospital Operations Table, Canadian Paediatric Society; France: The French Society of Neonatology & French Pediatric Society; India: National Neonatology Forum; Italy: Italian Society of Neonatology; Japan: Japanese Society for Neonatal Health and Development; Saudi Arabia: Ministry of Health; Singapore: KK Women's & Children's Hospital; South Korea: Korean Society of Neonatology; South Africa: Groote Schuur Hospital; Spain: Spanish Society of Neonatology; Sweden: Swedish Perinatal Society; Switzerland: Swissnos (Swiss National Center for Infection Prevention) and the Swiss Society of Obstetrics and Gynecology; UK: British Association of Perinatal Medicine; USA: Centers for Disease Control and Prevention, American Academy of Pediatrics.

\* available in a separate associated guideline

\*\* provisions made according to resources: if resources available and no evidence of community spread, for separation of mother-child

\*\*\* Separate guidelines endorsed by the Swiss Society of Neonatology

# Appropriate PPE for following: Contact precautions: use of gown, gloves, surgical mask; Droplet precautions: addition of protective eyewear; Airborne precautions: use of N95 mask or equivalent

Contact and Droplet: use gown, gloves, surgical mask and eye protection. Contact and Droplet and Airborne: use gown, gloves, eye protection plus N95 mask or equivalent, and preferably in negative pressure room

Abbreviations: AAP-American Academy of Pediatrics; AGP-aerosol generating procedures; CDC-Centers for Diseases Control and Prevention; BAL- bronchoalveolar lavage; BF-breastfeeding, EBM-expressed breastmilk; ET- endotracheal; LR- lower respiratory; NP-nasopharyngeal; OP-oropharyngeal; PCR-polymerase chain reaction



**Table 4. Summary of recommendations for the postnatal care of infants born to women with COVID-19**

|                             | Transmission-based precautions for clinical care                                                   | Separation of mother-infant                                                          | SARS-CoV-2 testing                                                   | Infant feeding               | Respiratory management                                                | Antiviral therapy |
|-----------------------------|----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------|-----------------------------------------------------------------------|-------------------|
| Asymptomatic newborn infant | Contact and droplet precautions                                                                    | If mother well, room-in with strict hygiene practices * +                            | NP/OP swabs for PCR if mother is positive (12-48h after birth) **    | Breastfeeding/EBM feeding*** | Not applicable                                                        | No recommended    |
| Symptomatic newborn infant  | Contact and droplet precautions, consider airborne precautions if requiring AGP and, or, intubated | In a separate room, negative pressure room if infant requires AGP and, or, intubated | NP/OP swabs for PCR if mother is positive (12-48h after delivery) ** | Breastfeeding/EBM feeding*** | Provision of respiratory support as clinically indicated <sup>Φ</sup> | Not recommended   |

\* mother should have face mask on at all times and observe strict compliance to hand hygiene. Infant cradle/crib to be placed at a distance of ≥2m

+ separation of mother-child can be considered with parental consultation and availability of local resources.


\*\* repeat testing 24-72h after first swab if negative

\*\*\* decision to breastfeed, feeding of expressed breastmilk should be done in discussion with the parents

Φ special care and considerations for potential aerosolization of secretions in infants on non-invasive support

Abbreviations: AGP: aerosol generating procedures; EBM: expressed breastmilk; NP: nasopharyngeal; OP: oropharyngeal; PCR: polymerase chain reaction

Delivery room and operating theatre management of infants born of mother with suspected or confirmed COVID-19



apa\_15495\_f1.png